Welcome to
synapcell blog
Home » Resources / Blog
Why Preclinical EEG Biomarkers?
EEG Biomarkers provide objective and functional measures of brain function and can be used to evaluate drugs efficacy or to phenotype a disease model.
SynapCell and Motac Neuroscience Discover New Biomarker of Parkinson’s Disease Progression!
This discovery, which combined Motac’s disease modeling and SynapCell’s EEG phenotyping capabilities, has been presented in a scientific communication during the SfN’s Neuroscience 2019 Annual Meeting in Chicago.
BetaPark – Translational EEG Biomarker
BetaPark is a translational EEG biomarker recorded in the motor cortex of both PD patients and animal models of prodromal and late-onset PD. Suppressed by dopaminergic drugs, BetaPark is used to quantify the efficacy of...
ASSR – Auditory Steady-State Response
Auditory Steady-State Response (ASSR) is a translational EEG biomarker of the brain’s ability to process sensory information. 40Hz ASSR responses are specifically lowered in patients and rodent models of schizophrenia, making it relevant to evaluate...
HPD – Hippocampal Paroxysmal Discharges
Mesio-temporal lobe epilepsy (MTLE) represents one of the most common forms of focal epilepsies. Generally resistant to most pharmacological treatments, this type of epilepsy affects about 10% of the total epileptic population.
SWD – Spike-and-Wave Discharges
Patients with Absence Epilepsy show generalized, non-convulsive seizures & typical Spike-and-Wave Discharges. The GAERS model displays spontaneous SWD and recapitulates most human disease features, making it clinically-relevant to evaluate new drugs for Absence Epilepsy.
PAC – Phase Amplitude Coupling
Phase-amplitude coupling can help study the interactions between neuronal oscillations. It describes a phenomenon whereby the amplitude of higher frequency activity is modulated by the phase of lower frequency activity, providing relevant information on Brain...
AERP – Auditory Evoked Event-Related Potentials
Event-related potentials are defined as the modification of the electrical activity of the nervous system in response to an external stimulation.
Cavion and SynapCell Present Significant Seizure-Suppressing Outcomes Using the GAERS Rat
Welcome to synapcell blog Cavion and SynapCell Present Significant Seizure-Suppressing Outcomes Using the GAERS Rat Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in SynapCell’s Genetic...
Pfizer and SynapCell Present Major Preclinical Efficacy Results Using the GAERS
Pfizer has developed PF-06372865 a new subtype-selective GABAA positive allosteric modulator, and selected SynapCell for the preclinical in vivo evaluation of the antiepileptic potential of its compound.
New Perspectives for SynapCell
SynapCell is accelerating its growth by moving into new premises where all its activities have been brought together.
Today is the international Epilepsy Day
An epileptic disorder is a chronic neurological condition characterized by recurrent epileptic seizures. Epileptic seizures are characterized by a hypersynchrony and hyperexcitability of one, or several, neural networks, leading to the apparition of spontaneous epileptiform...
A Word about AED Trials
Key Takeaways from the Anti Epileptic Drug and Devices Trials Conference
SynapCell mandated by UCB to enhance its epilepsy drug discovery program
Synapcell to assess the potential of UCB’s candidate molecules in the field of epilepsy. The two-year agreement will take advantage of SynapCell’s MTLE (mesial temporal lobe epilepsy) mouse solutions.
Epilepsy: Pitolisant’s promising early phase II study confirms the interest of SynapCell’s approach to AED discovery
The recent clinical data obtained with a new antiepileptic drug (AED) candidate called pitolisant, developed by Bioprojet, in an early Phase II study confirms the interest in SynapCell’s strategic approach, associating animal models and EEG,...
SynapCell to Screen for Novel Treatments for Pharmacoresistant Epilepsies
The University of Utah awards a subcontract to SynapCell to expand anti-seizure drug screening and testing capabilities in animal models of therapy-resistant epilepsy.